By Rebecca Robbins and Stephanie Nolen There is no clear path for African patients to get access to the treatments, which have multimillion-dollar price tags and are highly complex to manufacture and deliver.
Source: New Sickle Cell Therapies Will Be Out of Reach Where They Are Needed Most
Category: Sickle Cell Anemia, Genetic Engineering, Blood, Genetics and Heredity, Income Inequality, Bone Marrow, Drugs (Pharmaceuticals), Therapy and Rehabilitation, Developing Countries, Crispr (DNA), Transplants, Stem Cells, Food and Drug Administration, Vertex Pharmaceuticals Inc, Africa, your-feed-science, your-feed-healthcare
